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Abstract: Epidemiological studies support an independent inverse association between high-density
lipoprotein (HDL) cholesterol levels and heart failure incidence. The effect of selective HDL-raising
adeno-associated viral serotype 8-human apolipoprotein (apo) A-I (AAV8-A-I) gene transfer on
cardiac remodeling induced by transverse aortic constriction (TAC) was evaluated in C57BL/6
low-density lipoprotein receptor-deficient mice. Septal wall thickness and cardiomyocyte
cross-sectional area were reduced by 16.5% (p < 0.001) and by 13.8% (p < 0.01), respectively,
eight weeks after TAC in AAV8-A-I mice (n = 24) compared to control mice (n = 39). Myocardial
capillary density was 1.11-fold (p < 0.05) higher and interstitial cardiac fibrosis was 45.3% (p < 0.001)
lower in AAV8-A-I TAC mice than in control TAC mice. Lung weight and atrial weight were
significantly increased in control TAC mice compared to control sham mice, but were not increased
in AAV8-A-I TAC mice. The peak rate of isovolumetric contraction was 1.19-fold (p < 0.01) higher
in AAV8-A-I TAC mice (n = 17) than in control TAC mice (n = 29). Diastolic function was also
significantly enhanced in AAV8-A-I TAC mice compared to control TAC mice. Nitro-oxidative stress
and apoptosis were significantly reduced in the myocardium of AAV8-A-I TAC mice compared
to control TAC mice. In conclusion, selective HDL-raising human apo A-I gene transfer potently
counteracts the development of pressure overload-induced cardiomyopathy.
Keywords: high-density lipoproteins; gene therapy; cardiac hypertrophy; heart failure; pressure overload;
cardiac function; oxidative stress; apolipoprotein A-I
1. Introduction
High-density lipoproteins (HDLs) consist of several subclasses, which share the presence
of apolipoprotein (apo) A-I, phospholipids, and cholesterol but are distinct by the variable
abundance of one or more representatives of at least 85 proteins and hundreds of lipid species [1–3].
HDLs are circulating multimolecular platforms that exert divergent functions: reverse cholesterol
transport, anti-inflammatory effects, anti-oxidative effects, immunomodulatory effects, improved
endothelial function, increased endothelial progenitor cell number and function, antithrombotic effects,
and potentiation of insulin secretion and improvement of insulin sensitivity [4]. Pleiotropic effects of
HDL might be translated into clinically significant effects in strategically selected therapeutic areas
that are not directly related to native coronary artery disease [1–3].
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Epidemiological studies support a strong association between HDL cholesterol levels and
heart failure incidence. In Framingham Heart Study participants free of coronary heart disease
at baseline, low HDL cholesterol levels were independently associated with heart failure incidence
after adjustment for interim myocardial infarction and clinical covariates [5]. Apo A-I is the main
apo of HDL, and apo A-I levels strongly correlate with cholesterol levels. Human apo A-I gene
transfer inhibits the development of diabetic cardiomyopathy in rats [6]. HDL-raising gene transfer
improves diastolic function in hypercholesterolemic mice, as indicated by an increased peak rate of
isovolumetric relaxation [7]. Furthermore, human apo A-I gene transfer increases survival, reduces
infarct expansion, attenuates left ventricular dilatation, and enhances systolic and diastolic cardiac
function post-myocardial infarction in mice [8]. However, because beneficial effects of HDL-raising
gene therapy on cardiac function post-ligation of the left anterior descending coronary artery may be
dependent on improved infarct healing and reduced infarct expansion, direct effects of HDL on the
ventricular wall cannot be proven in this model of myocardial infarction.
Transverse aortic constriction (TAC) is a commonly used model for pressure overload-induced
cardiac hypertrophy and heart failure [9]. TAC initially leads to compensatory hypertrophy of the
heart, but over time, the response to chronic hemodynamic overload becomes maladaptive and results
in cardiac dilatation and heart failure. The general hypothesis investigated in the current study is
whether HDL-targeted human apo A-I gene therapy counteracts the development of non-ischemic
cardiomyopathy and heart failure in mice. Specifically, we evaluated the effect of hepatocyte-specific
adeno-associated viral (AAV) serotype 8-mediated human apo A-I gene therapy (AAV8-A-I) on the
cardiac structure and function and on the development of heart failure in C57BL/6 low-density
lipoprotein receptor (LDLr)-deficient mice subjected to pressure overload.
2. Results
2.1. Selective High-Density Lipoprotein (HDL)-Raising Gene Therapy Decreases Mortality after Transverse
Aortic Constriction (TAC)
HDL-raising gene transfer was performed at the age of 12 weeks in male C57BL/6 LDLr−/− mice
by the tail vein injection of 5 × 1010 genome copies of an AAV8 vector containing a hepatocyte-specific
expression cassette to induce the expression of human apo A-I (AAV8-A-I). Two weeks later, TAC
or sham operation was performed. AAV8-A-I gene transfer induced persistent and stable human
apo A-I expression for the entire duration of the experiment. Human apo A-I levels at 10 weeks after
gene transfer were 1730 ± 100 µg/mL (n = 10) in sham mice and 1780 ± 120 µg/mL (n = 10) in TAC
mice. AAV8-A-I gene therapy increased HDL cholesterol levels 1.47-fold (p < 0.001) in sham mice and
1.45-fold (p < 0.001) in TAC mice, whereas non-HDL cholesterol levels were not significantly altered
(Table 1). A comparison of Kaplan–Meier survival curves showed a clear trend (p = 0.0678) for a lower
mortality rate in AAV8-A-I TAC mice compared to control TAC mice (hazard ratio for mortality of
0.543; 95% confidence interval (CI): 0.282 to 1.05) during eight weeks of follow-up (Figure 1). Sham
operation did not result in any mortality (data not shown).
Table 1. Total, non-HDL, and HDL cholesterol plasma levels (mmol/L) in C57BL/6 LDLr−/− mice 10
weeks after gene transfer.
Parameter Control Sham AAV8-A-I Sham Control TAC AAV8-A-I TAC
Number of mice 10 10 10 10
Total cholesterol 5.56 ± 0.33 5.96 ± 0.21 5.84 ± 0.34 6.01 ± 0.23
Non-HDL cholesterol 4.42 ± 0.33 4.28 ± 0.25 4.70 ± 0.30 4.36 ± 0.25
HDL cholesterol 1.14 ± 0.05 1.68 ± 0.08 ◦◦◦ 1.14 ± 0.07 1.66 ± 0.09 ***
Data are expressed as means ± SEM (n = 10). ◦◦◦ p < 0.001 versus control sham. *** p < 0.001 versus control
TAC. HDL: high-density lipoproteins; TAC: transverse aortic constriction; AAV8-A-I: adeno-associated viral (AAV)
serotype 8 vector containing a hepatocyte-specific human apo A-I expression cassette.
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Figure 1. Comparison of Kaplan–Meier survival curves during an eight week follow-up period after 
transverse aortic constriction (TAC). Control TAC mice (red line) and adeno-associated viral serotype 
8-human apolipoprotein A-I (AAV8-A-I) TAC mice (green line) are compared. The 0 day time-point 
corresponds to the induction of TAC at the age of 14 weeks. Survival analysis was performed by log-
rank test. 
2.2. Atrial Hypertrophy, Lung Congestion, and Right Ventricular Hypertrophy in Control TAC Mice but 
Not in AAV8-A-I TAC Mice 
No significant difference in body weight, organ weights, or tibia length was observed between 
the different sham groups (Table 2). Heart weight was increased 1.66-fold (p < 0.001) in control TAC 
mice and 1.52-fold (p < 0.001) in AAV8-A-I TAC mice, compared to respective sham groups. 
Equivalent differences were observed for the heart weight/tibia length ratio (Table 2). Similarly, left 
ventricular weight was increased 1.87-fold (p < 0.001) in control TAC mice and 1.65-fold (p < 0.001) in 
AAV8-A-I TAC mice, compared to respective sham groups. Right ventricular weight was 1.33-fold 
(p < 0.001) higher in control TAC mice than in control sham mice but was not significantly elevated 
in AAV8-A-I TAC mice compared to AAV8-A-I sham mice (Table 2). Atrial weight was 2.05-fold (p < 
0.001) higher in control TAC mice than in control sham mice, whereas no significant alteration was 
observed in AAV8-A-I TAC mice compared to AAV8-A-I sham mice. Atrial weight was 45.7% (p < 
0.05) lower in AAV8-A-I TAC mice compared to control TAC mice. Lung weight was 1.13-fold (p < 
0.05) higher in control TAC mice than in control sham mice, whereas lung weight was not elevated 
at all in AAV8-A-I TAC mice. Lung weight was 13.3% (p < 0.05) lower in AAV8-A-I TAC mice 
compared to control TAC mice. Taken together, these data indicate left ventricular failure in control 
TAC mice, as evidenced by increased atrial weight, lung congestion, and right ventricular 
hypertrophy. In contrast, no evidence of heart failure was present in AAV8-A-I TAC mice. 
Table 2. Body weight and organ weights in C57BL/6 LDLr−/− mice. 
Parameter Control Sham AAV8-A-I Sham Control TAC AAV8-A-I TAC
Number of mice 10 10 11 9 
Body weight (g) 28.8 ± 0.6 29.7 ± 0.5 27.5 ± 0.3 29.2 ± 0.9 
Heart weight (mg) 135 ± 3 133 ± 7 224 ±18 §§§ 201 ± 7 §§§ 
Heart weight/tibia length (mg/mm) 7.78 ± 0.12 7.66 ± 0.40 12.7 ± 1.0 §§§ 11.5 ± 0.4 §§§ 
Left ventricular weight (mg) 86.9 ± 2.6 86.9 ± 5.0 163 ± 15 §§§ 143 ± 8 §§ 
Right ventricular weight (mg) 22.7 ± 0.8 24.2 ± 0.9 30.1 ± 2.0 §§§ 27.9 ± 2.7 
Atrial weight (mg) 9.10 ± 0.85 8.10 ± 0.92 18.6 ± 2.3 §§§ 10.1 ± 0.7 * 
Lung weight (mg) 152 ± 3 151 ± 2 171 ± 8 § 149 ± 3 * 
Tibia length (mm) 17.4 ± 0.1 17.3 ± 0.1 17.5 ± 0.1 17.6 ± 0.1 
Gene transfer was carried out in male C57BL/6 LDLr−/− mice at the age of 12 weeks. TAC or sham 
operation was performed at the age of 14 weeks. Mice were sacrificed eight weeks later.  
§ p <0 .05; §§ p < 0.01; §§§ p < 0.001 versus respective sham groups. * p < 0.05 versus control TAC. LDLr−/−: 
low-density lipoprotein receptor. 
Figure 1. Comparison of Kaplan–Meier survival curves during an eight week follow-up period after
transverse aortic constriction (TAC). Control TAC mice (red line) and adeno-associated viral serotype
8-human apolipoprotein A-I (AAV8-A-I) TAC mice (green line) are compared. The 0 day time-point
corresponds to the induction of TAC at the age of 14 weeks. Survival analysis was performed by
log-rank test.
2.2. Atrial Hypertrophy, Lung Congestion, and Right Ventricular Hypertrophy in Control TAC Mice but Not
in AAV8-A-I TAC Mice
No significant difference in body weight, organ weights, or tibia length was observed between the
different sham groups (Table 2). Heart weight was increased 1.66-fold (p < 0.001) in control TAC mice
and 1.52-fold (p < 0.001) in AAV8-A-I TAC mice, compared to respective sham groups. Equivalent
differences were observed for the heart weight/tibia length ratio (Table 2). Similarly, left ventricular
weight was increased 1.87-fold (p < 0.001) in control TAC ice and 1.65-fold (p < 0.001) in AAV8-A-I
TAC mice, compared to respective sham group . Right ventricular weight was 1.33-fold (p < 0.001)
higher in control TAC mice than in control sham mice but was not significantly eleva d in AAV8-A-I
TAC mice compared to AAV8-A-I sha mice (Table 2). Atrial weight was 2.05-fold (p < 0.001) higher
in control TAC mice than in control sham mice, whereas no significant alteration was observed in
AAV8-A-I TAC mice compared to AAV8-A-I sham mice. Atrial weight was 45.7% (p < 0.05) lower in
AAV8-A-I TAC mice compared to control TAC mice. Lung weight was 1.13-fold (p < 0.05) higher in
control TAC mice than in control sham mice, whereas lung weight was not elevated at all in AAV8-A-I
TAC mice. Lung weight was 13.3% (p < 0.05) lower in AAV8-A-I TAC mice compared to control TAC
mice. Taken together, these data indicate left ventricular failure in control TAC mice, as evidenced by
increased atrial weight, lung congestion, and right ventricular hypertrophy. In contrast, no evidence of
heart failure was present in AAV8-A-I TAC mice.
Table 2. Body weight and organ weights in C57BL/6 LDLr−/− mice.
Parameter Control Sham AAV8-A-I Sham Control TAC AAV8-A-I TAC
Number of mice 10 10 11 9
Body weight (g) 28.8 ± 0.6 29.7 ± 0.5 27.5 ± 0.3 29.2 ± 0.9
Heart weight (mg) 135 ± 3 133 ± 7 224 ±18 §§§ 201 ± 7 §§§
Heart weight/tibia length (mg/mm) 7.78 ± 0.12 7.66 0.40 12.7 ± 1.0 §§§ 11.5 ± 0.4 §§§
Left ventricular weight (mg) 86.9 2.6 86.9 ± 5.0 163 ± 5 §§§ 143 ± 8 §§
Right ventricular eight (mg) 22.7 ± 0.8 24.2 ± 0.9 30.1 ± 2.0 §§§ 27.9 ± 2.7
Atrial weight (mg) 9.10 ± 0.85 8.10 ± 0.92 18.6 ± 2.3 §§§ 10.1 ± 0.7 *
Lung weight (mg) 152 ± 3 151 ± 2 171 ± 8 § 149 ± 3 *
Tibia length (mm) 17.4 ± 0.1 17.3 ± 0.1 17.5 ± 0.1 17.6 ± 0.1
Gene transfer was carried out in male C57BL/6 LDLr−/− mice at the age of 12 weeks. TAC or sham operation was
performed at the age of 14 weeks. Mice were sacrificed eight weeks later. § p <0 .05; §§ p < 0.01; §§§ p < 0.001 versus
respective sham groups. * p < 0.05 versus control TAC. LDLr−/−: low-density lipoprotein receptor.
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2.3. AAV8-A-I Gene Transfer Counteracts Cardiac Hypertrophy, Increases Capillary Density and Relative
Vascularity, and Reduces Interstitial and Perivascular Fibrosis after TAC
Representative Sirius red-stained cross-sections of sham hearts and TAC hearts at day 56 after
operation are shown in Figure 2. TAC induced a significant increase of the left ventricular wall
area, anterior wall thickness, and septal wall thickness in both control TAC mice and in AAV8-A-I
TAC mice, compared to respective sham groups (Table 3). However, left ventricular hypertrophy
was less pronounced in AAV8-A-I TAC mice than in control TAC mice, as evidenced by a lower
ventricular wall area (p < 0.05), septal wall thickness (p < 0.001), and anterior wall thickness (p < 0.05;
Table 3). In addition, the cardiomyocyte cross-sectional area was 13.8% (p < 0.01) lower in AAV8-A-I
TAC mice than in control TAC mice. The capillary density and relative vascularity were 1.11-fold
(p < 0.05) and 1.10-fold (p < 0.05) higher, respectively, in AAV8-A-I TAC mice than in control TAC
mice (Table 3). A prominent decrease of interstitial (p < 0.01) and perivascular fibrosis (p < 0.001) was
observed in AAV8-A-I TAC mice compared to control TAC mice (Table 3). Figure 3 shows representative
photomicrographs of laminin-stained cardiomyocytes, CD31-positive capillaries, and Sirius red-stained
interstitial collagen viewed under polarized light. Taken together, AAV8-A-I gene therapy potently
counteracts pathological structural remodeling after TAC. Coronary atherosclerosis was completely
absent in all experimental groups (data not shown).
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Table 3. Morphometric and histological parameters of the left ventricular myocardium in C57BL/6
LDLr−/− mice.
Parameter Control Sham AAV8-A-I Sham Control TAC AAV8-A-I TAC
Number of mice 12 12 39 24
Left ventricular wall area (mm2) 10.4 ± 0.3 9.93 ± 0.30 14.2 ± 0.3 §§§ 13.1 ± 0.4 §§§,*
Septal wall thickness (µm) 1110 ± 20 990 ± 20 1430 ± 30 §§§ 1190 ± 30 §§,***
Anterior wall thickness (µm) 1130 ± 30 1090 ± 20 1420 ± 30 §§§ 1270 ± 30 §§,*
Cardiomyocyte cross-sectional area (µm2) 228 ± 8 228 ± 12 502 ± 13 §§§ 433 ± 21 §§§,**
Cardiomyocyte density (number/mm2) 4530 ± 180 4400 ± 160 2240 ± 60 §§§ 2680 ± 120 §§,*
Capillary density (number/mm2) 6400 ± 170 6020 ± 290 5330 ± 150 §§ 5910 ± 220 *
Relative vascularity (µm−2) 0.00632 ± 0.00020 0.00610 ± 0.00026 0.00487 ± 0.00014 §§§ 0.00536 ± 0.00020 §,*
Interstitial fibrosis (%) 0.939 ± 0.073 0.892 ± 0.083 9.98 ± 0.70 §§§ 5.46 ± 0.41 §§,**
Perivascular fibrosis (ratio) 0.291 ± 0.010 0.287 ± 0.019 0.880 ± 0.022 §§§ 0.562 ± 0.031 §,***
Gene transfer was carried out in male C57BL/6 LDLr−/− mice at the age of 12 weeks. TAC or sham operation was
performed at the age of 14 weeks. Mice were sacrificed eight weeks later. § p < 0.05; §§ p < 0.01; §§§ p < 0.001 versus
respective sham groups. * p < 0.05; ** p < 0.01; *** p < 0.001 versus control TAC.
2.4. Selective HDL-Raising Gene Therapy Improves Cardiac Function in Both Sham Mice and TAC Mice
AAV8-A-I gene therapy significantly improved diastolic function in sham mice, as evidenced by
a 1.19-fold (p < 0.05) increase of the absolute value of the peak rate of isovolumetric contraction and
a 14.5% (p < 0.05) reduction of the time constant of isovolumetric relaxation (Table 4). A prominent
and better cardiac function was observed in AAV8-A-I TAC mice compared to control TAC mice.
The end-diastolic pressure was significantly (p < 0.05) lower in AAV8-A-I TAC mice than in control TAC
mice. Selective HDL-raising gene transfer significantly improved systolic cardiac function in TAC mice,
as evidenced by a 1.18-fold (p < 0.01) increase of the peak rate of isovolumetric contraction. Diastolic
function in AAV8-A-I TAC mice was significantly better than in control TAC mice, as evidenced by
a 1.17-fold (p < 0.05) increase of the absolute value of the peak rate of isovolumetric relaxation and
a 15.4% (p < 0.05) decrease of the time constant of isovolumetric relaxation. Taken together, cardiac
function is significantly improved following AAV8-A-I gene transfer in both sham mice and TAC mice.
Table 4. Hemodynamic parameters in C57BL/6 LDLr−/− mice.
Parameter Control Sham AAV8-A-I Sham Control TAC AAV8-A-I TAC
Number of mice 10 12 29 16
LEFT VENTRICLE
Peak systolic pressure (mm Hg) 100 ± 2 102 ± 3 175 ± 5 §§§ 177 ± 6 §§§
End-diastolic pressure (mm Hg) 2.91 ± 0.32 2.63 ± 0.34 4.04 ± 0.48 2.12 ± 0.39 *
dP/dtmax (mm Hg/ms) 11.9 ± 1.1 12.5 ± 0.7 10.2 ± 0.3 12.1 ± 0.4 **
dP/dtmin (mmHg/ms) −9.32 ± 0.70 −11.1 ± 0.3 ◦ −10.3 ± 0.5 −12.1 ± 0.4 *
Tau (ms) 6.39 ± 0.43 5.47 ± 0.12 ◦ 6.32 ± 0.27 5.35 ± 0.14 *
Heart rate (bpm) 559 ± 19 601 ± 14 597 ± 9 629 ± 8
AORTA
Systolic pressure (mm Hg) 99.6 ± 2.5 101 ± 5 174 ± 6 §§§ 177 ± 7 §§§
Diastolic pressure (mm Hg) 61.9 ± 1.9 63.5 ± 2.0 58.2 ± 2.9 64.4 ± 3.6
Mean pressure (mm Hg) 79.8 ± 2.1 81.1 ± 2.3 98.8 ± 2.9 §§ 105 ± 3 §§§
Gene transfer was carried out in male C57BL/6 LDLr−/− mice at the age of 12 weeks. TAC or sham operation was
performed at the age of 14 weeks. Mice were sacrificed eight weeks later. ◦ p < 0.05 versus control sham; §§ p < 0.01;
§§§ p < 0.001 versus respective sham groups. * p < 0.05; ** p < 0.01 versus control TAC.
2.5. AAV8-A-I Gene Transfer Reduces Oxidative Stress and Myocardial Apoptosis after TAC
Plasma thiobarbituric acid-reactive substances (TBARS) and the 3-nitrotyrosine-positive area (%)
in the myocardium are shown in Figure 4A, B, respectively. No differences in plasma TBARS were
observed between different groups. Compared to respective sham groups, the 3-nitrotyrosine-positive
area (%) in the myocardium quantified by immunohistochemistry was increased 7.73-fold
(p < 0.001) and 3.57-fold (p < 0.001) in control TAC mice and in AAV8-A-I TAC mice, respectively.
The 3-nitrotyrosine-positive area was 57.6% (p < 0.001) lower in AAV8-A-I TAC mice than in control
Int. J. Mol. Sci. 2017, 18, 2012 6 of 14
TAC mice, indicating decreased nitro-oxidative stress. Apoptosis in the myocardium was evaluated
using immunohistochemical quantification of cleaved caspase-3. Cleaved caspase-3-positive cells were
scarce in the myocardium of sham mice (Figure 4C). Compared to control TAC mice, the number of
cleaved caspase-3-positive cells was reduced by 46.7% (p < 0.01) in AAV8-A-I TAC mice (Figure 4C).
Representative myocardial sections immunostained for 3-nitrotyrosine are shown in Figure 4D.
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following human apo A-I gene transfer [15], which is consistent with data on human apo A-I 
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Figure 4. Quantification of oxidative stress and cardiomyocyte apoptosis in sham mice and in
transverse aortic constriction (TAC) mice at day 56 after operation. Sham mice and TAC mice are
indicated by open bars and closed bars, respectively. Plasma thiobarbituric acid-reactive substances
(TBARS) expressed as plasma malondialdehyde equivalents, the percentage of 3-nitrotyrosine-positive
myocardial area, and cleaved caspase-3-positive cells in the myocardium are shown in panels (A–C),
respectively. Panel (D) illustrates representative photomicrographs showing myocardial sections
stained for 3-nitrotyrosine. All data represent means ± SEM (n = 10). Scale bar represents 50 µm.
3. Discussion
The main findings of the present study are the following: (1) selective HDL-raising gene therapy
exerts anti-hypertrophic effects under conditions of pressure overload; (2) AAV8-A-I gene transfer
counteracts features of pathological hypertrophy following pressure overload in mice, as evidenced by
reduced myocardial interstitial and perivascular fibrosis, an increased capillary myocardial density,
and reduced apoptosis in the myocardium; (3) selective HDL-raising gene therapy improves diastolic
cardiac function in both sham mice and in TAC mice and enhances systolic cardiac function in TAC
mice; (4) pulmonary congestion and right ventricular hypertrophy are observed in control TAC mice,
indicating the presence of left ventricular failure, which appears to be absent in AAV8-A-I TAC mice.
C57BL/6 LDLr−/− mice were chosen as a model, as the lipoprotein distribution in LDLr-deficient
mice, characterized by a predominance of apo B containing lipoproteins, resembles the human
lipoprotein distribution significantly more closely than wild-type mice, characterized by a
preponderance of HDL [10].
In the current study, a xenogeneic protein, human apo A-I, is expressed in mice. We have
consistently observed the absence of a humoral and cellular immune response against human apo A-I
in several murine strains after gene transfer with vectors containing a hepatocyte-specific expression
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cassette [11–14]. Human apo A-I gene transfer induces significant qualitative changes in HDL. We have
previously shown that murine apo A-I levels decreased to less than 25% of baseline levels following
human apo A-I gene transfer [15], which is consistent with data on human apo A-I transgenic mice [16].
This represents a post-transcriptional effect, as there is no decline of murine apo A-I mRNA levels [16].
Therefore, an important effect of human apo A-I gene transfer is the replacement of murine apo A-I
with human apo A-I. Secondly, control mice expressing murine apo A-I only contain a monodisperse
population of HDL particles with an average diameter of approximately 9.5 nm [16,17]. In contrast,
transgenic mice expressing human apo A-I exhibit a polydisperse population of HDL particles [16].
Consistent with these observations in transgenic mice, HDL particles following human apo A-I gene
transfer in mice were polydisperse with average diameters of 11, 9.7, 8.5 and 7.4 nm [18].
The vector applied in the current study contains a hepatocyte-specific expression cassette,
which restricts transgene expression to parenchymal liver cells. Human α1-antitrypsin
is only expressed in hepatocytes and macrophages, and the short version of the human
α1-antitrypsin promoter does not contain sequences to induce expression in macrophages [19].
The α1-microglobulin/bikunin precursor enhancer is located 2.7 kb downstream from its promoter
and is hepatocyte-specific [20–22]. The hepatic control region-1, previously described by Simonet et
al. [23], is also hepatocyte-specific. All the effects in the current study are systemic effects reflecting
secretion of human apo A-I by parenchymal liver cells.
Selective HDL-raising gene therapy exerted anti-hypertrophic effects on the myocardium under
conditions of pressure overload. HDL has been shown to downregulate the angiotensin II type 1
receptor [24,25]. Furthermore, HDL inhibits mechanical stress-induced autophagy and hypertrophy
in cultured cardiomyocytes [26]. Continuous infusion of HDL has been shown to inhibit cardiac
hypertrophy in vivo [25,26], which may be mediated at least in part via downregulation of the
angiotensin II type 1 receptor.
Overexpression of human apo A-I in mice has been shown to increase the activity of
two lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase,
which are critical for the anti-inflammatory and anti-oxidative potential of HDL [27]. An increased
anti-inflammatory and anti-oxidative potential of HDL may contribute to the beneficial effects of
AAV8-A-I gene transfer on cardiac remodeling after TAC. Features of pathological hypertrophy
are fibrotic remodeling, capillary rarefaction, and cardiomyocyte death, which promote cardiac
dysfunction and development of heart failure [28]. Reactive oxygen species and oxidative stress
contribute significantly to the pathophysiology of heart failure, having an impact on many key aspects
of the failing heart phenotype, such as hypertrophy, matrix remodeling, contractile dysfunction,
arrhythmia, and cell viability [29]. HDL-raising gene transfer in TAC mice reduced nitro-oxidative
stress in the heart and decreased apoptosis in the myocardium.
A prominent finding in the current study is that selective HDL-raising gene transfer enhances
diastolic function in sham mice. The observed effect of AAV8-A-I gene transfer on the diastolic function
in sham mice should be considered as a pharmacological effect that results in a supernormal diastolic
function. This finding is consistent with our previous observations on the effect of gene transfer with an
EAE3E4-deleted human apo A-I adenoviral vector on the cardiac function in female C57BL/6 LDLr−/−
mice [7]. The effect on the diastolic function occurred in the absence of detectable effects on the cardiac
structure and it is compatible with direct electrophysiological effects of HDL. Reconstituted HDL
shortens repolarization in isolated rabbit cardiomyocytes [30]. Moreover, the infusion of reconstituted
HDL decreases the heart rate-corrected QT interval on surface electrocardiograms in humans [30].
A prolonged QT interval is useful to predict left ventricular diastolic dysfunction [31]. Taken together,
the effects of HDL on the action potential and surface electrocardiogram are consistent with the effects
of raised HDL on diastolic function. The systolic function and diastolic function were improved in
AAV8-A-I TAC mice, compared to control TAC mice. Enhanced cardiac function in these mice was at
least in part due to the attenuation of pathological cardiac remodeling.
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A clear distinction should be made between cardiac dysfunction and heart failure. Heart failure in
humans is defined as a clinical syndrome characterized by typical symptoms (e.g., breathlessness and
fatigue) that may be accompanied by signs (e.g., elevated jugular venous pressure, pulmonary crackles,
and peripheral oedema) caused by structural and/or functional cardiac abnormalities, resulting
in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress [32].
This definition of heart failure restricts itself to stages at which clinical symptoms are apparent.
Because subjective evidence of disease cannot be evaluated in animals, diagnosis of heart failure in
mice is entirely dependent on objective clinical signs. The presence of increased wet lung weight
indicating pulmonary congestion can be used for an operational diagnosis of heart failure in mice.
Increased lung weight in control TAC mice but not in AAV8-A-I TAC mice is compatible with the
absence of congestive heart failure in the latter. The presence of increased atrial weight in control TAC
mice but not in AAV8-A-I TAC mice also suggests the presence of chronically elevated filling pressures
in the former.
Left ventricular pressure overload after TAC initially induces reactive interstitial fibrosis and is
subsequently followed by replacement fibrosis in areas of cardiomyocyte cell death [33]. Perivascular
inflammation and fibrosis may decrease tissue availability to oxygen and nutrients and increase
the pathological remodeling response [34]. Selective HDL-raising gene therapy potently inhibited
interstitial and perivascular fibrosis after TAC. HDL has been shown to reduce transforming growth
factor-ß1-induced collagen deposition in murine fibroblasts [35]. Furthermore, HDL has been
demonstrated to decrease transforming growth factor-ß1-induced endothelial-mesenchymal transition
in aortic endothelial cells in vitro [36]. An improved anti-oxidative and anti-inflammatory potential
of HDL after AAV8-A-I gene therapy may explain the reduced perivascular fibrosis in AAV8-A-I
TAC mice.
The current study was restricted to male mice, because significant sex differences in the degree
of left ventricular hypertrophy after TAC exist [37,38]. This sex difference would increase variability
within the same experimental group and would decrease the statistical power of a study in which
mice of both sexes are compared. Moreover, sex differences in mice do not predict sex differences
in humans. The observed effects in the current study are strong. It is reasonable to assume that
the data on improved cardiac structure and function following AAV8-A-I gene transfer are robust
and are therefore reproducible in female mice or in other genetic backgrounds. Clearly, interaction
effects between treatment on the one hand and sex or genetic background on the other hand cannot be
entirely excluded.
AAV8-mediated gene transfer has been used successfully to treat haemophilia B in a clinical
trial [39]. AAV vectors have a theoretical potential for clinical translation. Therefore, this study
represents an important step forward in comparison with previous HDL-raising gene therapy
studies [40–44].
In conclusion, the current study demonstrates that HDL exerts beneficial effects on cardiac
structure and function in the absence of coronary artery disease. Selective HDL-raising gene therapy
improves cardiac function both in the absence and in the presence of pressure overload and counteracts
adverse ventricular remodeling in mice with pressure overload. These data indicate that HDL-targeted
therapies may have a potential for the prevention and treatment of non-ischemic cardiomyopathy.
4. Materials and Methods
4.1. In Vivo Experiments Evaluating the Effect of HDL-Raising Gene Transfer on the Development of Pressure
Overload-Induced Cardiomyopathy
All experimental procedures in animals were performed in accordance with protocols approved
by the Institutional Animal Care and Research Advisory Committee of the Catholic University of
Leuven (approval number: P154/2013, 1 October 2013). Male C57BL/6 LDLr−/− mice, originally
purchased from Jackson Laboratories (Bar Harbor, ME, USA), were fed a standard chow (SC) diet (Sniff
Spezialdiäten GMBH, Soest, Germany) following weaning and for the entire duration of the experiment.
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Gene transfer was performed at the age of 12 weeks. HDL-raising gene transfer was performed by
the tail vein injection of 5 × 1010 genome copies of an AAV8 vector containing a hepatocyte-specific
expression cassette to induce the expression of human apo A-I (AAV8-A-I). The expression cassette
of this vector consists of the 1272 bp DC172 promoter, comprising an 890 bp α1-antitrypsin promoter
fused together with two copies of the 160 bp α1-microglobulin enhancer [45], upstream of the 2 kb
genomic human apo A-I sequence, one copy of the 774 bp hepatic control region-1, and the rabbit β-globin
polyadenylation signal (127 bp). AAV vector production was performed as described [46]. The control
AAV8-null vectors contained the transcriptional regulatory sequences but no genomic human apo
A-I insert.
To induce pressure overload, TAC was performed at the age of 14 weeks as described [47].
Briefly, anesthesia was performed with a single intraperitoneal injection of sodium pentobarbital
(Nembutal, Ceva Sante Animale, Brussels, Belgium) at a dose of 40–70 mg/kg. The mice were put
in a supine position and the temperature was maintained at 37 ◦C with a heating pad. A horizontal
skin incision of 0.5 to 1 cm in length was made at the level of the suprasternal notch. A 2 to 3 mm
longitudinal cut was made in the proximal portion of the sternum, and the thymus gland was retracted.
This allowed for visualization of the aortic arch under low-power magnification. A wire with a snare
at the end was passed under the aorta between the origin of the right innominate artery and the left
common carotid artery. A 7-0 silk suture (Ethicon, Johnson & Johnson, Livingston, Scotland, UK)
was snared with the wire and pulled back around the aorta. Subsequently, a bent 27-gauge needle
(BD Microlance, BD, Franklin Lakes, NJ, USA) was placed next to the aortic arch and the suture was
snugly tied around the needle and the aorta. Afterwards, the needle was quickly removed. The skin
was closed and the mice were allowed to recover on a warming pad until they were fully awake.
The sham procedure was identical except that no constriction on the aorta was applied. Buprenorphine
(Temgesic; Reckitt Benckiser Healthcare Ltd., Hull, UK) was administered at a dose of 0.1 mg/kg
body weight subcutaneously for peri-operative pain relief. Postoperative analgesia was applied
immediately following the intervention. The euthanasia of mice at day 56 after sham or TAC operation
was performed by cervical dislocation.
Group assignment at the start of the study was performed at random. At the end of the study,
data of all surviving mice were included in the analysis. Investigators who performed the endpoint
analyses were blinded to the group allocation. The unblinding of animal numbers corresponding to
specific allocation groups was performed at the completion of measurements. The total number of mice
included in the current study was 166. This number comprised 22 control sham mice, 22 AAV8-A-I
sham mice, 80 control TAC mice, and 42 AAV8-A-I TAC mice. No sham mice died during the
experiment, whereas 30 control TAC mice and 9 AAV8-A-I TAC mice died.
4.2. In Vivo Hemodynamic Measurements
Invasive hemodynamic measurements were performed eight weeks after TAC or after sham
operation as described [47]. The mice were anesthetized by the intraperitoneal administration of
1.4 g/kg urethane (Sigma, Steinheim, Germany). Body temperature was maintained with a heating
pad and monitored with a rectal probe. An incision in the right carotid artery was made with a
26-gauge needle between a distal and proximal non-occlusive ligation of the artery. A 1.0 French Millar
pressure catheter (SPR-67/NR; Millar instruments, Houston, TX, USA) was inserted and advanced to
the left ventricle (LV). After the stabilization of the catheter, the heart rate, maximal systolic LV pressure,
minimal diastolic LV pressure, peak rate of isovolumetric LV contraction (dP/dtmax), and peak rate of
isovolumetric LV relaxation (dP/dtmin) were measured. The end-diastolic LV pressure was calculated
manually from the pressure in the function of time curves. The time constant of isovolumetric LV
pressure fall (tau) was calculated using the method of Weiss et al. [48]. Arterial blood pressure
measurements were obtained after the withdrawal of the catheter from the LV to the ascending aorta.
Data were registered with Powerlab Bridge Amplifier and Chart software (sampling rate of 2000 Hz;
ADInstruments Ltd., Oxford, UK).
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4.3. Blood Sampling
Blood (volume of 600–800 µL) was obtained by a puncture of the vena cava inferior at the end
of the experiment just before euthanasia. Anticoagulation was performed with a 0.1 volume of
136 mmol/L trisodium citrate, and plasma was immediately isolated by centrifugation at 1100× g for
10 min and stored at −20 ◦C.
4.4. Plasma Lipoprotein Analysis
Plasma levels of total cholesterol and free cholesterol were determined using a Cholesterol
Quantification kit from Sigma (Sigma, St. Louis, MO, USA). Lipoproteins were separated from 25 µL
of citrate-anticoagulated plasma using a photopolymerized loading gel stained with Sudan black dye
(Lipoprint, Los Angeles, CA, USA) [49]. The samples were subjected to electrophoresis for 60 min
at 3 mA per gel tube, set at a maximum delivery of 500 V. Bands were identified on the basis of the
migration distance, according to the instructions of the manufacturer.
4.5. Human Apo A-I Enzyme-Linked Immunosorbent Assay
Human apo A-I plasma levels were determined by an enzyme-linked immunosorbent
assay (ELISA), according to the instructions of the manufacturer (Abcam, Cambridge Science
Park, UK). Standards and samples were added to the wells, followed by the antibody mix.
After incubation, the wells were washed to remove unbound material, and the chromogenic
3,3′,5,5′-tetramethylbenzidine substrate solution was added. In the presence of horseradish peroxidase
enzyme conjugates, 3,3′,5,5′-tetramethylbenzidine and peroxide react, leading to the production of
3,3′,5,5′-tetramethylbenzidine diimine, which causes the solution to take a blue color with a maximum
absorbance at 605 nm. The color intensity is proportional to the amount of horseradish peroxidase
activity, which in turn is related to the levels of bound analyte and thus to the human apo A-I in
the plasma. The addition of acidic stop solution changes the color from blue to yellow (absorbance
maximum at 450 nm), which stabilizes the color development to enable accurate measurement of
the intensity at 450 nm using a spectrophotometer. A blank was subtracted from the standards and
samples. A standard curve was created by plotting the logarithm of the absorbance of each standard
versus the logarithm of the soluble factor concentration. The correlation coefficient corresponding to
the regression curve was 0.99 or higher. No cross-reaction with murine apo A-I was observed.
4.6. Analysis of Lipid Peroxidation in Plasma
Measurement of TBARS used for the quantification of lipid peroxidation was performed according
to the instructions of the manufacturer (Cayman Chemical, Ann Arbor, MI, USA).
4.7. Histological and Morphometric Analysis
Histological and morphometric analyses were executed as described [47]. After hemodynamic
analysis, the mice were perfused via the abdominal aorta with phosphate-buffered saline (PBS) and
the hearts were arrested in diastole by CdCl2 (100 µL; 0.1 mol/L), followed by perfusion fixation
with 1% paraformaldehyde in PBS. After dissection, the hearts were post-fixated overnight in 1%
paraformaldehyde, embedded in paraffin, and 6 µm thick cross-sections at 130 µm spaced intervals
were made extending from the apex to the basal part of the LV. LV remodeling was assessed by
morphometric analysis on mosaic images of Sirius red-stained heart cross-sections using Axiovision
4.6 software (Zeiss, Zaventem, Belgium). Anterior wall thickness and septal wall thickness were
determined. All geometric measurements were computed in a blinded fashion from representative
tissue sections of four separate regions, and the average value was used to represent that animal for
statistical purposes [8,50].
To measure collagen content in the interstitium, Sirius red staining was performed as described by
Junqueira et al. [51]. Sirius red polarization microscopy on a Leica RBE microscope with KS300 software
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(Zeiss) was used to quantify thick, tightly packed mature collagen fibers as orange-red birefringent
and loosely packed, less cross-linked and immature collagen fibers as yellow-green birefringent.
Collagen-positive area was normalized to the LV remote area and was expressed as a percentage.
Any perivascular fibrosis was excluded from this analysis. Perivascular fibrosis was quantified as the
ratio of the fibrosis area surrounding the vessel to the total vessel area. Two mid-ventricular sections
were studied per animal [47].
Cardiomyocyte hypertrophy was analyzed on paraffin sections stained with rabbit anti-mouse
laminin (Sigma; 1/50) by measuring the cardiomyocyte cross-sectional area (µm2) of at least
200 randomly selected cardiomyocytes in the LV myocardium. The capillary density in the myocardium
was determined on CD31-stained sections using rat anti-mouse CD31 antibodies (BD; 1/500). Relative
vascularity in the myocardium was determined as (capillary density (number/mm2)/cardiomyocyte
density (number/mm2))/(cardiomyocyte cross-sectional area (µm2)) [6]. Two mid-ventricular
cross-sections were analyzed per mouse [8,50].
Immunostaining for 3-nitrotyrosine was performed with rabbit anti-nitrotyrosine antibodies
(Merck Millipore, Overijse, Belgium; dilution of 1/250).
Apoptosis was quantified on deparaffinized tissue sections using a SignalStain-cleaved caspase-3
IHC detection kit (Cell Signaling Technologies, Beverly, MA, USA), which utilizes a polyclonal rabbit
antibody to the neoepitope peptide at the end of cleaved caspase-3 [9].
4.8. Statistical Analysis
All data are expressed as means ± standard error of the means (SEM). Parameters between four
groups were compared by one-way analysis of variance followed by Bonferroni multiple comparisons
post-test for comparing sham groups, TAC groups, and sham versus respective TAC groups using
GraphPad Instat (GraphPad Software, San Diego, CA, USA). When the assumption of sampling
from populations with identical standard deviations was not met, a logarithmic transformation
was performed. When the assumption of sampling from populations with Gaussian distributions
was not met, a Kruskal–Wallis test was performed, followed by Dunn’s multiple comparison
post-test. Parameters between two groups were compared using the Student’s t-test. When indicated,
a logarithmic transformation or a non-parametric Mann–Whitney test was performed. The assumption
of Gaussian distribution was tested using the Kolmogorov–Smirnov method. Kaplan–Meier survival
curves were analyzed by a log-rank test using Prism4 (GraphPad Software, San Diego, CA, USA).
A two-sided p-value of less than 0.05 was considered statistically significant.
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